Development and Validation of a Stability-Indicating Reversed-Phase HPLC Method for Simultaneous Estimation of Rosuvastatin and Ezetimibe from Their Combination Dosage Forms
 
More details
Hide details
1
Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad-382481, Gujarat State, India
CORRESPONDING AUTHOR
Anuradha K. Gajjar   

Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad-382481, Gujarat State, India
Publication date: 2017-10-08
 
Eurasian J Anal Chem 2010;5(3):265–283
 
KEYWORDS
ABSTRACT
A simple, precise and rapid stability-indicating reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed and subsequently validated for the simultaneous estimation of Rosuvastatin (RSV) and Ezetimibe (EZE) from their combination drug product. The proposed method is based on the separation of the two drugs in reverse phase mode using Hypersil C18 150 x 4.6 mm, 5µ column maintained at a temperature of 40°C. The optimum mobile phase consisted of 0.05 M phosphate buffer (pH 2.5)-Methanol (45+55, v/v), mobile phase flow rate of 1.0 mL min-1 and UV detection was set at 242 nm. Rosuvastatin, Ezetimibe and their combination drug product were exposed to thermal, photolytic, hydrolytic and oxidative stress conditions and the stressed samples were analyzed by the proposed method. There were no interfering peaks from excipients, impurities or degradation products due to variable stress conditions and the proposed method is specific for the simultaneous estimation of RSV and EZE in the presence of their degradation products. The method was validated according to ICH guidelines. It was found to be accurate and reproducible. Linearity was obtained in the concentration range of 5-80 mg mL-1 for both RSV and EZE with correlation coefficients of 0.99999 and 0.99994 respectively. % Mean recovery of triplicate samples at each level for both the drugs were found in the range of 98% to 102% with % RSD of less than 2.0%. The proposed method can be successfully applied in the quality control of bulk manufacturing and pharmaceutical dosage forms.
 
REFERENCES (25)
1.
Lennernas H and Fager G (1997) Pharmacodynamic and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet 32: 403.
 
2.
Nissen S E, Nicholls S J, Sipahi I, Libby P, Raichlen J S, Ballantyne C M, Davignon J, Erbel R, Fruchart J C, Tardif J C, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M and Tuzcu E M (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13): 1556.
 
3.
Leitersdorf E (2002) Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int J Clin Pract 56: 116.
 
4.
Heek M V, Farley C, Compton D, Hoos L and Davis H R (2001) Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Phamacol 134(2): 409.
 
5.
Dujovne A, Ettinger M P, McNeer F, Lipka L, Lebeaut A P, Suresh R, Yang B and Veltri E P (2002) Efficacy and Safety of a Potent New Selective Cholesterol Absorption Inhibitor, Ezetimibe, in Patients With Primary Hypercholesterolemia. Am J Cardiol 90: 1092.
 
6.
ICH (1993) Proceedings of the International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use. Stability Testing of New Drug Substances and Products, Q1A. Geneva, Switzerland.
 
7.
ICH (1996) Proceedings of the International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use. Photostability Testing of New Drug Substances and Products, Q1B. Geneva, Switzerland.
 
8.
United States Pharmacopoeia 26 (2003) U.S. Pharmacopoeial Convention Inc, Rockville: p 1151.
 
9.
Kumar T R, Shitut N R, Kumar P K, Vinu M C, Kumar V V, Mullangi R and Srinivas N R (2006) Determination of Rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. Biomed Chromatogr 20: 881.
 
10.
Suslu I, Celebier M and Altinoz S (2007) Determination of Rosuvastatin in Pharmaceutical Formulations by Capillary Zone Electrophoresis. Chromatographia 66: 65.
 
11.
Uyar B, Celebier M and Altinoz S (2007) Spectrophotometric determination of Rosuvastatin calcium in tablets. Pharmazie 62: 411.
 
12.
Sane R T, Kamat S S, Menon S N, Inamdar S R and Mote M R (2007) Determination of Rosuvastatin calcium in its bulk drug and pharmaceutical preparations by highperformance thin-layer chromatography. J Planar Chromatogr 18: 194.
 
13.
Vittal S, Kumar T R, Shitut N R, Vinu M C, Kumar V V and Mullangi R (2006) Simultaneous quantitation of Rosuvastatin and Gemfibrozil in human plasma by highperformance liquid chromatography and its application to a pharmacokinetic study. Biomed Chromatogr 20: 1252.
 
14.
Sistla R, Tata V S, Kashyap Y V, Chandrasekar D and Diwan P V (2005) Development and validation of a reversed-phase HPLC method for the determination of Ezetimibe in pharmaceutical dosage forms. J Pharm Biomed Anal 39: 517.
 
15.
Doshi A S, Kachhadia P K and Joshi H (2008) Validation of a stability-indicating LC method for assay of Ezetimibe in tablets and for determination of content uniformity. Chromatographia 67: 137.
 
16.
Akmar S K, Kothapalli L, Thomas A, Jangam S and Deshpande A D (2007) Reverse Phase HPLC method for the estimation of Ezetimibe in bulk and pharmaceutical formulations. Indian J Pharm Sci 69(5): 695.
 
17.
Oswald S, Scheuch E, Cascorbi I and Siegmund W (2006) A LC–MS/MS method to quantify the novel cholesterol lowering drug Ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Anal Technol Biomed Life Sci 830: 143.
 
18.
Li S, Liu G, Jia J, Li X and Yu C J (2006) Liquid chromatography–negative ion electrospray tandem mass spectrometry method for the quantification of Ezetimibe in human plasma. J Pharm Biomed Anal 40(4): 987.
 
19.
Oliveira P R, Brum L L, Fronza M, Bernardi L S, Masiero S M and Dalmora S L (2006) Development and validation of a Liquid Chromatography-Tandem Mass Spectrometry method for the determination of Ezetimibe in human plasma and pharmaceutical formulations. Chromatographia 63(7-8): 315.
 
20.
Chaudhari B G, Patel M N, Shah P B, Patel L J and Patel V P (2007) Stabilityindicating reversed-phase liquid chromatography method for simultaneous determination of Atrovastatin and Ezetimibe from their combination drug products. J AOAC Int 90(6): 1539.
 
21.
Mehta T N, Patel A K, Kulkarni G M and Suubbaiah G (2005) Determination of Rosuvastatin in the presence of its degradation products by a stability-indicating LC method. J AOAC Int 88(4): 1142.
 
22.
Singh S, Singh B, Bahuguna R, Wadhwa L and Saxena R (2006) Stress degradation studies on Ezetimibe and development of a validated stability-indicating HPLC assay. J Pharm Biomed Anal 41: 1037.
 
23.
Rajkondawar V V (2006) Simultaneous Estimation of Rosuvastatin and Ezetimibe by Reverse Phase High Performance Liquid Chromatography. Asian J Chem 18(4): 3230.
 
24.
Snyder L R, Kirkland J J, Glajch L J (1997) Practical HPLC Method Development 2nd edition, John Wiley and Sons Inc: New York, p 709.
 
25.
ICH (1996) Proceedings of the International Conference on Harmonisation of Technical Requirement of Registration of Pharmaceuticals for Human Use (ICH Harmonised Tripartite Guidelines). Validation of Analytical Procedures: Methodology, Q2B, Geneva, Switzerland.
 
eISSN:1306-3057